New chemo cocktail targets rare small bowel tumors
NCT ID NCT06835387
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a four-drug chemotherapy combination called NALIRIFOX in 36 adults with advanced small bowel adenocarcinoma that cannot be removed by surgery. The drugs are given intravenously on days 1 and 15 of each 28-day cycle for up to 6 cycles, followed by a milder maintenance treatment. The main goal is to see how many patients' tumors shrink or disappear.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NALIRIFOX (nanoliposomal irinotecan, oxaliplatin, fluorouracil, and folinic acid)
What this could lead to
If successful, this could provide a new treatment option to shrink or control advanced small bowel tumors that cannot be removed by surgery.
What could go wrong
This is a small, early-phase trial with only 36 participants, so results may not apply to everyone. Chemotherapy side effects like nausea, nerve damage, and low blood counts are expected risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL BOWEL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Atlantic Health System
RECRUITINGMorristown, New Jersey, 07960, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Parkview Research Center
RECRUITINGFort Wayne, Indiana, 46845, United States
Contact
Contact Phone: •••-•••-••••
-
University of Illinois Cancer Center
RECRUITINGChicago, Illinois, 60612, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Texas Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
Contact Email: •••••@•••••
Contact
-
Virginia Commonwealth University
RECRUITINGRichmond, Virginia, 23298, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact Email: •••••@•••••
Contact